Metsera, Inc.
DelistedCIK 2040807fmd_07WH32RHKP46KAK1K7MY4KE89NManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2023 to Sep 30, 2025, 8 periods
| Line item | FY2023 | FY2024 |
|---|---|---|
| Research and development | 16 | 108 |
| Total operating expenses | 44 | 225 |
| Operating income | (44) | (225) |
| Interest expense | – | 0 |
| Interest and investment income | 2 | 6 |
| Other non-operating income (expense) | (5) | 0 |
| Income before taxes | (47) | (218) |
| Income tax expense | 0 | (9) |
| Net income from continuing operations | (47) | (209) |
| Net income | (47) | (209) |